IPSC (STOCKS)
Century Therapeutics, Inc. Common Stock
$2.290000
+0.040000 (+1.78%)
Prev close: $2.250000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Brent Pfeiffenberger
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $409.41M
- Employees
- 165
- P/E (TTM)
- -2.07
- P/B (TTM)
- 1.56
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
8
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.11 | $-0.16 | +0.0512 | +31.76% |
|
Dec 2025 (Q4)
|
$-0.22 | $-0.29 | +0.0690 | +23.88% |
|
Sep 2025 (Q3)
|
$-0.32 | $-0.34 | +0.0243 | +7.06% |
|
Jun 2025 (Q2)
|
$-0.38 | $-0.38 | +0.0035 | +0.91% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $7.28M |
| Operating Expenses | $115.12M |
| Operating Income/Loss | -$115.12M |
| Income/Loss From Continuing Operations After Tax | -$107.78M |
| Income/Loss From Continuing Operations Before Tax | -$107.85M |
| Net Income/Loss | -$107.78M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$107.78M |
| Net Income/Loss Available To Common Stockholders, Basic | -$107.78M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.14 |
| Diluted Earnings Per Share | -$1.14 |
| Basic Average Shares | 366,420,715 |
| Diluted Average Shares | 366,343,284 |
| Assets | $326.55M |
| Current Assets | $139.04M |
| Noncurrent Assets | $187.51M |
| Fixed Assets | $47.61M |
| Intangible Assets | $34.20M |
| Other Non-current Assets | $105.71M |
| Liabilities | $61.81M |
| Current Liabilities | $13.57M |
| Accounts Payable | $3.15M |
| Wages | $1.49M |
| Other Current Liabilities | $8.92M |
| Noncurrent Liabilities | $48.24M |
| Equity | $264.74M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $264.74M |
| Liabilities And Equity | $326.55M |
| Net Cash Flow From Operating Activities | -$94.52M |
| Net Cash Flow From Operating Activities, Continuing | -$94.52M |
| Net Cash Flow From Investing Activities | -$33.04M |
| Net Cash Flow From Investing Activities, Continuing | -$33.04M |
| Net Cash Flow From Financing Activities | $126.68M |
| Net Cash Flow From Financing Activities, Continuing | $126.68M |
| Net Cash Flow | -$883.00K |
| Net Cash Flow, Continuing | -$883.00K |
| Comprehensive Income/Loss | -$108.45M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$108.67M |
| Other Comprehensive Income/Loss | -$35.09M |